MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boobis, A. R.
Right arrow Articles by Davies, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boobis, A. R.
Right arrow Articles by Davies, D. S.

Substrate specificity of the form of cytochrome P-450 catalyzing the 4- hydroxylation of debrisoquine in man

AR Boobis, S Murray, GC Kahn, GM Robertz and DS Davies

In the present study we have investigated the substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man by analyzing the kinetics of inhibition of this activity by potential alternative substrates for the enzyme. All three compounds for which there is good in vivo evidence for an association between their metabolism and the debrisoquine oxidation polymorphism (viz., sparteine, guanoxan and phenformin) were potent competitive inhibitors of the reaction. The Ki for sparteine was 85 microM, for guanoxan it was 30 microM, and for phenformin it was 205 microM. Two compounds, acetanilide and antipyrine, for which the in vivo evidence was against an association between their metabolism and that of debrisoquine, were weak, noncompetitive inhibitors of debrisoquine 4- hydroxylase activity. The Ki values were 1.23 mM and 19.3 mM, respectively. Two additional compounds, tolbutamide and amylobarbitone, for which the in vivo evidence was also against an association between their metabolism and the debrisoquine oxidation polymorphism, did not appreciably inhibit the reaction. In fact, amylobarbitone caused a slight stimulation of activity. It is concluded that debrisoquine 4- hydroxylase is a specific form of cytochrome P-450 with a well-defined substrate specificity. Furthermore, it should be possible to identify compounds that might be subject to an oxidation polymorphism prior to the exposure of any subjects to the compound.

Volume 23, Issue 2, pp. 474-481, 03/01/1983
Copyright © 1983 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
P. J. Murphy
The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 2, 1959-1983
Drug Metab. Dispos., June 1, 2008; 36(6): 981 - 985.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Schulz-Utermoehl, R. J. Edwards, and A. R. Boobis
Affinity and Potency of Proinhibitory Antipeptide Antibodies Against CYP2D6 Is Enhanced using Cyclic Peptides as Immunogens
Drug Metab. Dispos., May 1, 2000; 28(5): 544 - 551.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1983 by the American Society for Pharmacology and Experimental Therapeutics